Health and Wealth, en podd från BioStock om investeringar i life science

"Den stora uppsidan har vi fortfarande framför oss!" Efter mer än 20 år på Genovis, där han gått den långa vägen från labb-assistent till vd, har Fredrik Olsson en tydlig vison för bolagets fortsatta tillväxtresa. Genom att ligga nära kunderna – ofta globala läkemedelsjättar – kan Genovis erbjuda exakt de verktyg kunderna efterfrågar för analys och tillverkning inom snabbväxande områden som ADC:s och Genomics. Och, med den ödmjuka inställningen att "det finns mer kunskap utanför Genovis än i bolaget", är fler strategiska förvärv likt SEQURNA troligen att vänta för Kävlingebolaget.

Join Cereno Scientific’s CEO Sten Sörensen and CMO/R&D Head Rahul Agrawal for a deep-dive into the company’s mission, strategic evolution, and future outlook. From Sten’s pharma journey to Rahul’s global R&D insights, discover how their complementary leadership is driving innovation in cardiovascular disease treatment. Don’t miss this one-hour conversation on biotech, partnerships, and what’s next for Cereno.

Years before becoming an expert healthcare investor, a young Claus Henrik Johansen was sitting at his office desk, slightly bored. From the adjacent room he could hear the equity investors at work, shouting and laughing and seemingly having a blast. Then and there, he decided to shift focus from tech and macroeconomics to equity investing in healthcare – and never looked back. Twenty years later, he has his own investment fund; Global Health Invest which he founded and listed on the Nasdaq stock exchange. Tune in as Claus Henrik Johansen tells his story and explains why he had to start his fund, reveals the fundamentals of his investment strategy (and how he sleeps at night) and shares his view on the current market landscape and which global companies he believes will move the needle in the years to come.

From his childhood venture as a self-employed gardener, to multi-exit entrepreneur and seasoned business angel currently co-raising a 500 MSEK life science fund. Kristofer Klerfalk shares his personal story and insights on being a founder friendly investor, how you review +1000 pitch cases annually (hint: listening to classical music helps!) and the internal checklist he uses to spot a great investment opportunity.

A conversation with Calliditas former CEO Renée Aguiar-Lucander on leadership, courage and transitioning from an early career in the male-dominated world of international finance and investment banking, to breaking new ground as a life science leader on a challenging but rewarding journey towards a multi-billion dollar sale of the company.

Søren Lemonius, founder and managing partner at Sunstone Life Science Ventures, shares the story of how he and his team initiated the Danish VC firm’s investment strategy that has lead to a number of very successful exits – and to some very costly losses. He also reveals why early-stage deals often yield the best returns (”because you’re selling a multiple of a dream”), explains why venture capital thrives in times of crisis and shares the one major reason for why some investments never materialise. We ponder the concept of longevity and find out what Søren considers to be the next hot areas to invest in, why IPOs are not a prefered exit option for Sunstone’s investments and why venture capital firms usually thrive in times of crisis.